ImmunoGen (IMGN) Given a $18.00 Price Target at HC Wainwright

HC Wainwright set a $18.00 price objective on ImmunoGen (NASDAQ:IMGN) in a research report sent to investors on Monday. The firm currently has a buy rating on the biotechnology company’s stock.

IMGN has been the subject of a number of other reports. Zacks Investment Research upgraded ImmunoGen from a hold rating to a buy rating and set a $6.50 target price for the company in a report on Tuesday, October 31st. BidaskClub upgraded ImmunoGen from a hold rating to a buy rating in a report on Thursday, January 18th. Cantor Fitzgerald reiterated a hold rating and issued a $5.00 target price on shares of ImmunoGen in a report on Friday, November 3rd. Finally, Royal Bank of Canada reiterated an outperform rating and issued a $12.00 target price on shares of ImmunoGen in a report on Thursday, February 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. ImmunoGen has a consensus rating of Buy and an average target price of $9.10.

Shares of ImmunoGen (NASDAQ:IMGN) opened at $10.15 on Monday. The firm has a market capitalization of $1,340.00, a P/E ratio of -9.95 and a beta of 2.50. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. ImmunoGen has a 1-year low of $2.40 and a 1-year high of $10.66.

ImmunoGen (NASDAQ:IMGN) last issued its earnings results on Friday, February 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03). The business had revenue of $39.40 million during the quarter, compared to analyst estimates of $39.62 million. The business’s quarterly revenue was up 185.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.39) EPS. equities analysts anticipate that ImmunoGen will post -1.04 EPS for the current year.

In other ImmunoGen news, Director Daniel M. Junius sold 46,667 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $10.01, for a total value of $467,136.67. Following the completion of the sale, the director now owns 243,367 shares of the company’s stock, valued at $2,436,103.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.51% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership acquired a new stake in ImmunoGen in the second quarter valued at approximately $102,000. Intl Fcstone Inc. acquired a new stake in ImmunoGen in the second quarter valued at approximately $115,000. Raymond James Financial Services Advisors Inc. acquired a new stake in ImmunoGen in the second quarter valued at approximately $126,000. Virginia Retirement Systems ET AL acquired a new stake in ImmunoGen in the third quarter valued at approximately $136,000. Finally, SG Americas Securities LLC grew its stake in ImmunoGen by 75.7% in the fourth quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 7,937 shares during the period. 67.97% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/02/15/immunogen-imgn-given-a-18-00-price-target-at-hc-wainwright.html.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply